The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Inclusion Criteria: * Men and women aged between 19 to 65 years old * Subjects attaining ≥grade 2 (moderate) in the investigator's rating of the severity of glabellar lines at maximum frown * Fertile women who have properly agreed to contraception during the clinical trial period * Subjects who voluntarily sign the informed consent Exclusion Criteria: * Subjects who answered 'Yes' any of the C-SSRS questions (only Phase I) * Subjects with the general neuromuscular synaptic disorder(e.g. Myasthenia gravis, Lambert-Eaton syndrome) * Subjects who suffer from muscle weakness or paralysis in the forehead area * Subjects with infection, skin disorders, or scars at the glabellar region. * Subjects with noticeable facial asymmetry * Subjects with allergy or hypersensitivity to the botulinum toxin or their components * Subjects who have taken Anti-Coagulant, Anti-Platelet agent, Aspirin and NSAIDs within 7 days prior to administration of the investigational drug * Subjects who were injected facial with botulinum toxin within the past 6 months or whose dose exceeds 200 U for the whole body * Subjects with previous treatment of Face Lifting, Permanent Implant, and/or Filler in the glabellar region * Subjects who are participating in other clinical trials or have participated in other clinical trials within 4 weeks of the screening date. * A history of drug or alcohol abuse * Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception * Subjects who are not eligible for this study based on the judgment of an investigator